Scott Freeman

Scott has extensive experience in clinical trial work and FDA regulatory strategy. As the CMO of Savant he was the primary investigator behind the National Institutes of Health (NIH) grant in bringing 18-MC to IND and its first-in-human clinical trial. He served as Vice President of Clinical Development at Onyx Pharmaceutical and was head of both the clinical development and operations groups, which lead to FDA approval of Nexavar for kidney and liver cancer. Dr. Freeman was an Associate Professor at Tulane University and a guest researcher at the NIH in both basic and clinical research. Scott earned his BA from the University of Colorado and received his MD from the University of Nevada.